Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

N. De Stefano, M. Filippi, D. Miller, P. J. Pouwels, A. Rovira, A. Gass, C. Enzinger, P. M. Matthews, D. L. Arnold

    Research output: Contribution to journalReview articleAcademicpeer-review

    Abstract

    Proton MR spectroscopy (MRS) allows noninvasive characterization of chemical-pathologic changes in the brain. In patients with multiple sclerosis (MS), proton MRS reveals chemical pathology in focal inflammatory lesions as well as in regions of the brain that are not associated with structural abnormalities on conventional MRI. In MS studies, it has been particularly useful as a method for the assessment of neurodegeneration based on decreases in the levels of the neuro-axonal marker compound, N-acetylaspartate. Also, MRS has provided evidence of chemical pathology and repair involving non-neuronal brain cells based on changes in metabolites, including choline, myo-inositol, glutamate, and GABA. Despite its greater pathologic specificity for axonal integrity compared to conventional MRI, MRS has been used only infrequently in clinical trials. This prompted us to review current MRS clinical applications in MS, discuss the potential and limitations of the technique, and suggest recommendations for the application of MRS to clinical trials.

    Original languageEnglish
    Pages (from-to)1942-1952
    Number of pages11
    JournalNeurology
    Volume69
    Issue number20
    DOIs
    Publication statusPublished - 1 Jan 2007

    Cite this

    De Stefano, N., Filippi, M., Miller, D., Pouwels, P. J., Rovira, A., Gass, A., ... Arnold, D. L. (2007). Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology, 69(20), 1942-1952. https://doi.org/10.1212/01.wnl.0000291557.62706.d3
    De Stefano, N. ; Filippi, M. ; Miller, D. ; Pouwels, P. J. ; Rovira, A. ; Gass, A. ; Enzinger, C. ; Matthews, P. M. ; Arnold, D. L. / Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. In: Neurology. 2007 ; Vol. 69, No. 20. pp. 1942-1952.
    @article{246d8c081a134528828d6a9f6025c030,
    title = "Guidelines for using proton MR spectroscopy in multicenter clinical MS studies",
    abstract = "Proton MR spectroscopy (MRS) allows noninvasive characterization of chemical-pathologic changes in the brain. In patients with multiple sclerosis (MS), proton MRS reveals chemical pathology in focal inflammatory lesions as well as in regions of the brain that are not associated with structural abnormalities on conventional MRI. In MS studies, it has been particularly useful as a method for the assessment of neurodegeneration based on decreases in the levels of the neuro-axonal marker compound, N-acetylaspartate. Also, MRS has provided evidence of chemical pathology and repair involving non-neuronal brain cells based on changes in metabolites, including choline, myo-inositol, glutamate, and GABA. Despite its greater pathologic specificity for axonal integrity compared to conventional MRI, MRS has been used only infrequently in clinical trials. This prompted us to review current MRS clinical applications in MS, discuss the potential and limitations of the technique, and suggest recommendations for the application of MRS to clinical trials.",
    author = "{De Stefano}, N. and M. Filippi and D. Miller and Pouwels, {P. J.} and A. Rovira and A. Gass and C. Enzinger and Matthews, {P. M.} and Arnold, {D. L.}",
    year = "2007",
    month = "1",
    day = "1",
    doi = "10.1212/01.wnl.0000291557.62706.d3",
    language = "English",
    volume = "69",
    pages = "1942--1952",
    journal = "Neurology",
    issn = "0028-3878",
    publisher = "Lippincott Williams and Wilkins",
    number = "20",

    }

    De Stefano, N, Filippi, M, Miller, D, Pouwels, PJ, Rovira, A, Gass, A, Enzinger, C, Matthews, PM & Arnold, DL 2007, 'Guidelines for using proton MR spectroscopy in multicenter clinical MS studies' Neurology, vol. 69, no. 20, pp. 1942-1952. https://doi.org/10.1212/01.wnl.0000291557.62706.d3

    Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. / De Stefano, N.; Filippi, M.; Miller, D.; Pouwels, P. J.; Rovira, A.; Gass, A.; Enzinger, C.; Matthews, P. M.; Arnold, D. L.

    In: Neurology, Vol. 69, No. 20, 01.01.2007, p. 1942-1952.

    Research output: Contribution to journalReview articleAcademicpeer-review

    TY - JOUR

    T1 - Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

    AU - De Stefano, N.

    AU - Filippi, M.

    AU - Miller, D.

    AU - Pouwels, P. J.

    AU - Rovira, A.

    AU - Gass, A.

    AU - Enzinger, C.

    AU - Matthews, P. M.

    AU - Arnold, D. L.

    PY - 2007/1/1

    Y1 - 2007/1/1

    N2 - Proton MR spectroscopy (MRS) allows noninvasive characterization of chemical-pathologic changes in the brain. In patients with multiple sclerosis (MS), proton MRS reveals chemical pathology in focal inflammatory lesions as well as in regions of the brain that are not associated with structural abnormalities on conventional MRI. In MS studies, it has been particularly useful as a method for the assessment of neurodegeneration based on decreases in the levels of the neuro-axonal marker compound, N-acetylaspartate. Also, MRS has provided evidence of chemical pathology and repair involving non-neuronal brain cells based on changes in metabolites, including choline, myo-inositol, glutamate, and GABA. Despite its greater pathologic specificity for axonal integrity compared to conventional MRI, MRS has been used only infrequently in clinical trials. This prompted us to review current MRS clinical applications in MS, discuss the potential and limitations of the technique, and suggest recommendations for the application of MRS to clinical trials.

    AB - Proton MR spectroscopy (MRS) allows noninvasive characterization of chemical-pathologic changes in the brain. In patients with multiple sclerosis (MS), proton MRS reveals chemical pathology in focal inflammatory lesions as well as in regions of the brain that are not associated with structural abnormalities on conventional MRI. In MS studies, it has been particularly useful as a method for the assessment of neurodegeneration based on decreases in the levels of the neuro-axonal marker compound, N-acetylaspartate. Also, MRS has provided evidence of chemical pathology and repair involving non-neuronal brain cells based on changes in metabolites, including choline, myo-inositol, glutamate, and GABA. Despite its greater pathologic specificity for axonal integrity compared to conventional MRI, MRS has been used only infrequently in clinical trials. This prompted us to review current MRS clinical applications in MS, discuss the potential and limitations of the technique, and suggest recommendations for the application of MRS to clinical trials.

    UR - http://www.scopus.com/inward/record.url?scp=36049000228&partnerID=8YFLogxK

    U2 - 10.1212/01.wnl.0000291557.62706.d3

    DO - 10.1212/01.wnl.0000291557.62706.d3

    M3 - Review article

    VL - 69

    SP - 1942

    EP - 1952

    JO - Neurology

    JF - Neurology

    SN - 0028-3878

    IS - 20

    ER -